Anti-IL-20 monoclonal antibodies have been evaluated as clinical candidates for the treatment and/or prevention of psoriasis, rheumatoid arthritis, atherosclerosis, osteoporosis, stroke and also bacterial lung infections [30]. The gene discussed is IL20; the disease is osteoporosis.